Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

<p>Abstract</p> <p>Background</p> <p>EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypot...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Wang Fen, Wang Shuhang, Wang Zhijie, Duan Jianchun, An Tongtong, Zhao Jun, Bai Hua, Wang Jie
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2012-08-01
Серии:Journal of Experimental & Clinical Cancer Research
Предметы:
EGFR phosphorylation
EGFR mutation
Non-small cell lung cancer
Online-ссылка:http://www.jeccr.com/content/31/1/65
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы